Bacterial vesicles block viral replication in macrophages via TLR4-TRIF-axis.
Alveolar epithelial cell
Antiviral innate immunity
Bacterial and viral co-infection
Extracellular vesicles
Macrophage
Outer membrane vesicles
Pneumonia
Journal
Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464
Informations de publication
Date de publication:
28 03 2023
28 03 2023
Historique:
received:
08
11
2022
accepted:
23
02
2023
medline:
30
3
2023
entrez:
28
3
2023
pubmed:
29
3
2023
Statut:
epublish
Résumé
Gram-negative bacteria naturally secrete nano-sized outer membrane vesicles (OMVs), which are important mediators of communication and pathogenesis. OMV uptake by host cells activates TLR signalling via transported PAMPs. As important resident immune cells, alveolar macrophages are located at the air-tissue interface where they comprise the first line of defence against inhaled microorganisms and particles. To date, little is known about the interplay between alveolar macrophages and OMVs from pathogenic bacteria. The immune response to OMVs and underlying mechanisms are still elusive. Here, we investigated the response of primary human macrophages to bacterial vesicles (Legionella pneumophila, Klebsiella pneumoniae, Escherichia coli, Salmonella enterica, Streptococcus pneumoniae) and observed comparable NF-κB activation across all tested vesicles. In contrast, we describe differential type I IFN signalling with prolonged STAT1 phosphorylation and strong Mx1 induction, blocking influenza A virus replication only for Klebsiella, E.coli and Salmonella OMVs. OMV-induced antiviral effects were less pronounced for endotoxin-free Clear coli OMVs and Polymyxin-treated OMVs. LPS stimulation could not mimic this antiviral status, while TRIF knockout abrogated it. Importantly, supernatant from OMV-treated macrophages induced an antiviral response in alveolar epithelial cells (AEC), suggesting OMV-induced intercellular communication. Finally, results were validated in an ex vivo infection model with primary human lung tissue. In conclusion, Klebsiella, E.coli and Salmonella OMVs induce antiviral immunity in macrophages via TLR4-TRIF-signaling to reduce viral replication in macrophages, AECs and lung tissue. These gram-negative bacteria induce antiviral immunity in the lung through OMVs, with a potential decisive and tremendous impact on bacterial and viral coinfection outcome. Video Abstract.
Identifiants
pubmed: 36978183
doi: 10.1186/s12964-023-01086-4
pii: 10.1186/s12964-023-01086-4
pmc: PMC10045439
doi:
Substances chimiques
Adaptor Proteins, Vesicular Transport
0
TLR4 protein, human
0
Toll-Like Receptor 4
0
TICAM1 protein, human
0
Types de publication
Video-Audio Media
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
65Informations de copyright
© 2023. The Author(s).
Références
J Clin Invest. 2012 Nov;122(11):4037-47
pubmed: 23041628
BMJ Open Respir Res. 2016 Feb 23;3(1):e000113
pubmed: 26933507
Front Immunol. 2020 Feb 14;11:80
pubmed: 32117243
Front Med (Lausanne). 2020 Nov 06;7:571003
pubmed: 33240904
Eur Respir J. 2004 Feb;23(2):327-33
pubmed: 14979512
PLoS Pathog. 2016 Apr 22;12(4):e1005592
pubmed: 27105429
Infect Immun. 2020 Jun 22;88(7):
pubmed: 32253250
Respir Res. 2018 Jun 25;19(1):126
pubmed: 29940963
PLoS One. 2013;8(4):e60078
pubmed: 23565187
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Virol. 2015 Dec;89(23):11935-44
pubmed: 26378172
J Gen Virol. 2015 Aug;96(8):2086-2091
pubmed: 25934792
BMC Infect Dis. 2012 Jun 21;12:139
pubmed: 22721450
Vet Res. 2014 Apr 09;45:42
pubmed: 24712747
Front Immunol. 2019 Sep 24;10:2275
pubmed: 31616438
Int J Mol Sci. 2018 Aug 10;19(8):
pubmed: 30103446
BMC Microbiol. 2017 Nov 13;17(1):216
pubmed: 29132302
Annu Rev Microbiol. 2010;64:163-84
pubmed: 20825345
Virology. 2010 Jan 20;396(2):178-88
pubmed: 19913271
J Vis Exp. 2018 May 9;(135):
pubmed: 29806827
J Immunol. 2013 Aug 1;191(3):1250-9
pubmed: 23804714
Microbiol Mol Biol Rev. 2010 Mar;74(1):81-94
pubmed: 20197500
Adv Drug Deliv Rev. 2021 Sep;176:113811
pubmed: 34022269
PLoS One. 2010 Dec 23;5(12):e15692
pubmed: 21203418
PLoS Pathog. 2013;9(11):e1003773
pubmed: 24278020
Sci Rep. 2017 Sep 20;7(1):11988
pubmed: 28931863
Infect Immun. 2010 Sep;78(9):3822-31
pubmed: 20605984
J Immunol. 2007 Dec 1;179(11):7692-701
pubmed: 18025215
Int J Mol Sci. 2020 Jun 21;21(12):
pubmed: 32575921
PLoS One. 2012;7(11):e49856
pubmed: 23185463
J Proteomics. 2014 Jun 25;106:46-60
pubmed: 24769240
Virol J. 2006 Aug 31;3:63
pubmed: 16945126
Cell Microbiol. 2015 May;17(5):607-20
pubmed: 25363599
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
J Innate Immun. 2020;12(1):63-73
pubmed: 30557876
Small. 2020 Oct;16(40):e2003158
pubmed: 32885611
BMC Res Notes. 2017 Mar 9;10(1):121
pubmed: 28274266
Trends Microbiol. 2015 Mar;23(3):154-63
pubmed: 25572883
Front Immunol. 2020 Oct 30;11:598636
pubmed: 33250899
Virulence. 2019 Dec;10(1):902-909
pubmed: 31657264
mBio. 2016 Oct 18;7(5):
pubmed: 27795394